Description

Investment or Collaboration

While HIFU (a highly precise non-invasive medical procedure using high-intensity focused ultrasound to destroy pathogenic tissue) has been used to treat more than 80000 cancer patients to date, a number of factors have limited its wider uptake in the clinic as a standard of care treatment for patients with solid tumours. Current HIFU devices can require extensive treatment times that often exceed 4 hours and can result in significant collateral damage. To address these and other limitations a research team at Imperial College, London, have developed Acublate, a proprietary HIFU system, which addresses a number of the existing limitations of HIFU treatment to enable HIFU to become a more effective and economically feasible alternative to currently available procedures.

The Acublate technology has many applications including, but not limited to:

• curative or palliative ablation for primary or secondary cancer;
• ablation of uterine fibroids;
• other clinical applications including vascular, neurosurgery, cardiac, ocular, orthopaedic, and targeted therapy; and
• cosmetic correction

Download the PDF of Phased Array High Intensity Focused Ultrasound (HIFU) Technology

For more information please contact

Dr Roisin NicAmhlaoibh

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)